{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:57:44Z","timestamp":1791046664496,"version":"4.1.0"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2018.00257","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T14:33:44Z","timestamp":1537367624000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":66,"title":["Neprilysin Inhibitors and Bradykinin"],"prefix":"10.3389","volume":"5","author":[{"given":"Duncan J.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"46172","DOI":"10.1074\/jbc.M407333200","article-title":"A three-dimensional model of the neprilysin 2 active site based on the X-ray structure of neprilysin","volume":"279","author":"Voisin","year":"2004","journal-title":"J Biol Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1042\/bj3630697","article-title":"Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin","volume":"363","author":"Rose","year":"2002","journal-title":"Biochem J."},{"key":"B4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/bj3270023","article-title":"Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin","volume":"327","author":"Hoang","year":"1997","journal-title":"Biochem J."},{"key":"B5","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1016\/S0021-9258(18)42915-8","article-title":"Membrane-bound aminopeptidase P from bovine lung","volume":"267","author":"Simmons","year":"1992","journal-title":"J Biol Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"34390","DOI":"10.1074\/jbc.M110.120576","article-title":"Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay","volume":"285","author":"Ouimet","year":"2010","journal-title":"J Biol Chem."},{"key":"B7","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1074\/jbc.270.25.15262","article-title":"Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum","volume":"270","author":"Emoto","year":"1995","journal-title":"J Biol Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/00005344-200036051-00009","article-title":"Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH","volume":"36","author":"Fahnoe","year":"2000","journal-title":"J Cardiovasc Pharmacol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1006\/abbi.1998.0913","article-title":"Soluble human endothelin-converting enzyme-1: expression, purification, and demonstration of pronounced pH sensitivity","volume":"359","author":"Ahn","year":"1998","journal-title":"Arch Biochem Biophys."},{"key":"B10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/FJC.0b013e318210fc7e","article-title":"Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat","volume":"57","author":"Hegde","year":"2011","journal-title":"J Cardiovasc Pharmacol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/jm970041e","article-title":"Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase","volume":"40","author":"Robl","year":"1997","journal-title":"J Med Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1124\/jpet.105.084749","article-title":"Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24","volume":"315","author":"Sulpizio","year":"2005","journal-title":"J Pharmacol Exp Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/jm00010a014","article-title":"Dicarboxylic acid dipeptide neutral endopeptidase inhibitors","volume":"38","author":"Ksander","year":"1995","journal-title":"J Med Chem."},{"key":"B15","unstructured":"Assessment Report: Entresto.2015"},{"key":"B16","unstructured":"BrownPC Center for Drug Evaluation and Research. Application Number 207620Orig1s000. Pharmacology Review2015"},{"key":"B17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition - implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Bas","year":"2015","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1605767","article-title":"Inhibiting plasma kallikrein for hereditary angioedema prophylaxis","volume":"376","author":"Banerji","year":"2017","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fmed.2018.00003","article-title":"Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease","volume":"5","author":"Schmaier","year":"2018","journal-title":"Front Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1016\/j.febslet.2008.05.046","article-title":"Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences","volume":"582","author":"Whyteside","year":"2008","journal-title":"FEBS Lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/0-306-46826-3_25","article-title":"The neprilysin family in health and disease","volume":"477","author":"Turner","year":"2000","journal-title":"Adv Exp Med Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1128\/MCB.24.10.4428-4437","article-title":"Reduced fertility in male mice deficient in the zinc metallopeptidase NL1","volume":"24","author":"Carpentier","year":"2004","journal-title":"Mol Cell Biol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1016\/S0021-9258(18)98378-X","article-title":"Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II)","volume":"268","author":"Jaspard","year":"1993","journal-title":"J Biol Chem."},{"key":"B26","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1021\/bi00282a035","article-title":"Human kidney \u201cenkephalinase\u201d, a neutral metalloendopeptidase that cleaves active peptides","volume":"22","author":"Gafford","year":"1983","journal-title":"Biochemistry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1042\/bj2230433","article-title":"The metabolism of neuropeptides","volume":"223","author":"Matsas","year":"1984","journal-title":"Biochem J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"11227","DOI":"10.1021\/bi00035a032","article-title":"Purification and properties of membrane-bound aminopeptidase P from rat lung","volume":"34","author":"Orawski","year":"1995","journal-title":"Biochemistry"},{"key":"B29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1432-1033.1991.tb16035.x","article-title":"Aminopeptidase P from rat brain","volume":"198","author":"Harbeck","year":"1991","journal-title":"Eur J Biochem."},{"key":"B30","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/0006-2952(84)90122-9","article-title":"Hydrolysis of opioid hexapeptides by carboxypeptidase N","volume":"33","author":"Skidgel","year":"1984","journal-title":"Biochem Pharmacol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0021-9258(18)94167-0","article-title":"Human carboxypeptidase M","volume":"264","author":"Skidgel","year":"1989","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/bbrc.1995.1569","article-title":"Substrate specificity differences between recombinant rat testes endopeptidase EC 3","volume":"209","author":"Lew","year":"1995","journal-title":"Biochem Biophys Res Commun."},{"key":"B33","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1074\/jbc.274.7.4053","article-title":"Hydrolysis of peptide hormones by endothelin-converting enzyme-1","volume":"274","author":"Johnson","year":"1999","journal-title":"J Biol Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"14704","DOI":"10.1074\/jbc.M211242200","article-title":"Characterization of endothelin-converting enzyme-2","volume":"278","author":"Mzhavia","year":"2003","journal-title":"J Biol Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"H1069","DOI":"10.1152\/ajpheart.2000.278.4.H1069","article-title":"Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma","volume":"278","author":"Kuoppala","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0196-9781(95)00006-6","article-title":"Degradation of lysylbradykinin by endopeptidase 24","volume":"16","author":"Rosenbaum","year":"1995","journal-title":"Peptides"},{"key":"B37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1471-4159.1979.tb05176.x","article-title":"Purification and properties of a prolyl endopeptidase from rabbit brain","volume":"33","author":"Orlowski","year":"1979","journal-title":"J Neurochem."},{"key":"B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-291X(79)91581-X","article-title":"Degradation of bradykinin by isolated neutral endopeptidases of brain and pituitary","volume":"90","author":"Wilk","year":"1979","journal-title":"Biochem Biophys Res Commun."},{"key":"B39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0031-6997(25)00449-1","article-title":"Neutral endopeptidase 24","volume":"45","author":"Roques","year":"1993","journal-title":"Pharmacol Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1073\/pnas.86.1.297","article-title":"Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24","volume":"86","author":"Shipp","year":"1989","journal-title":"Proc Natl Acad Sci USA."},{"key":"B41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood.V76.4.775.775","article-title":"Comparative levels of CALLA\/neutral endopeptidase on normal granulocytes, leukemic cells, and transfected COS-1 cells","volume":"76","author":"Tran-Paterson","year":"1990","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1042\/bst0210663","article-title":"Endopeptidase-24","volume":"21","author":"Kenny","year":"1993","journal-title":"Biochem Soc Trans."},{"key":"B43","doi-asserted-by":"publisher","first-page":"10662","DOI":"10.1073\/pnas.88.23.10662","article-title":"CD10\/neutral endopeptidase 24","volume":"88","author":"Shipp","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"key":"B44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1590\/S0100-879X2000000600008","article-title":"Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides","volume":"33","author":"Campbell","year":"2000","journal-title":"Braz J Med Biol Res."},{"key":"B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)00058-4","article-title":"Bioregulation of kinins: kallikreins, kininogens, and kininases","volume":"44","author":"Bhoola","year":"1992","journal-title":"Pharmacol Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/978-1-4615-9543-4_61","article-title":"Basic pharmacology of kinins: pharmacologic receptors and other mechanisms","author":"Regoli","year":"1989","journal-title":"Adv Exp Med Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/01.HYP.21.2.155","article-title":"Bradykinin peptides in kidney, blood, and other tissues of the rat","volume":"21","author":"Campbell","year":"1993","journal-title":"Hypertension"},{"key":"B48","doi-asserted-by":"publisher","first-page":"R897","DOI":"10.1152\/ajpregu.2000.278.4.R897","article-title":"Kinins in humans","volume":"278","author":"Duncan","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1161\/01.HYP.34.2.171","article-title":"Angiotensin converting enzyme inhibition modifies angiotensin, but not kinin peptide levels in human atrial tissue","volume":"34","author":"Campbell","year":"1999","journal-title":"Hypertension"},{"key":"B50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2005","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0022-3565(25)38895-6","article-title":"Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin","volume":"269","author":"Ryan","year":"1994","journal-title":"J Pharmacol Exp Ther."},{"key":"B52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nm0897-904","article-title":"The control of microvascular permeability and blood pressure by neutral endopeptidase","volume":"3","author":"Lu","year":"1997","journal-title":"Nature Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-0115(93)90268-D","article-title":"Sensory neuropeptide release by bradykinin: mechanisms and pathophysiological implications","volume":"47","author":"Geppetti","year":"1993","journal-title":"Regul Pept."},{"key":"B54","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0196-9781(84)90020-2","article-title":"Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase","volume":"5","author":"Skidgel","year":"1984","journal-title":"Peptides"},{"key":"B55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1385\/JMN:18:1-2:129","article-title":"Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide","volume":"18","author":"Fischer","year":"2002","journal-title":"J Mol Neurosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nbd.2008.11.002","article-title":"Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase","volume":"35","author":"Kramer","year":"2009","journal-title":"Neurobiol Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1084\/jem.181.6.2271","article-title":"Neutral endopeptidase modulation of septic shock","volume":"181","author":"Lu","year":"1995","journal-title":"J Exp Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1152\/jappl.1999.87.4.1266","article-title":"Targeted deletion of the neutral endopeptidase gene alters ventilatory responses to acute hypoxia in mice","volume":"87","author":"Grasemann","year":"1999","journal-title":"J Appl Physiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e4590","DOI":"10.1371\/journal.pone.0004590","article-title":"Improved learning and memory in aged mice deficient in amyloid \u00df-degrading neutral endopeptidase","volume":"4","author":"Walther","year":"2009","journal-title":"PLoS ONE"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(04)17142-0","article-title":"Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies","volume":"364","author":"Debiec","year":"2004","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.24612","article-title":"Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2","volume":"79","author":"Higuchi","year":"2016","journal-title":"Ann Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ajhg.2016.07.008","article-title":"Rare variants in MME, encoding metalloprotease neprilysin, are linked to late-onset autosomal-dominant axonal polyneuropathies","volume":"99","author":"Auer-Grumbach","year":"2016","journal-title":"Am J Hum Genet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1212\/NXG.0000000000000094","article-title":"MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43)","volume":"2","author":"Depondt","year":"2016","journal-title":"Neurol Genet."},{"key":"B64","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FPC.0b013e328363c137","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"23","author":"Pare","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"B65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0022-3565(24)37829-2","article-title":"Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats","volume":"287","author":"Campbell","year":"1998","journal-title":"J Pharmacol Exp Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1042\/cs0600491","article-title":"Opposite effects of captopril on angiotensin I-converting enzyme \u2018activity\u2019 and \u2018concentration\u2019; relation between enzyme inhibition and long-term blood pressure response","volume":"60","author":"Boomsma","year":"1981","journal-title":"Clin Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0014-2999(94)00450-1","article-title":"Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes","volume":"264","author":"Helin","year":"1994","journal-title":"Eur J Pharmacol."},{"key":"B68","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0022-3565(25)38250-9","article-title":"Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension","volume":"265","author":"Pham","year":"1993","journal-title":"J Pharmacol Exp Ther."},{"key":"B69","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0022-3565(24)39065-2","article-title":"Metabolism of bradykinin in vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite","volume":"294","author":"Murphey","year":"2000","journal-title":"J Pharmacol Exp Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1254\/jjp.60.111","article-title":"A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma","volume":"60","author":"Shima","year":"1992","journal-title":"Jpn J Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/rcm.565","article-title":"Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry","volume":"16","author":"Marshall","year":"2002","journal-title":"Rapid Commun Mass Spectrom."},{"key":"B72","doi-asserted-by":"publisher","first-page":"H1340","DOI":"10.1152\/ajpheart.1996.271.4.H1340","article-title":"Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: Influence of enalaprilat","volume":"271","author":"D\u00e9carie","year":"1996","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0196-9781(99)00020-0","article-title":"Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P","volume":"20","author":"Blais","year":"1999","journal-title":"Peptides"},{"key":"B74","doi-asserted-by":"publisher","first-page":"H275","DOI":"10.1152\/ajpheart.2001.281.1.H275","article-title":"Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma","volume":"281","author":"Cyr","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"H2182","DOI":"10.1152\/ajpheart.2001.280.5.H2182","article-title":"Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats","volume":"280","author":"Dendorfer","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/0006-2952(89)90290-6","article-title":"Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum","volume":"38","author":"Sheikh","year":"1989","journal-title":"Biochem Pharmacol."},{"key":"B77","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/00004872-199210120-00006","article-title":"Bradykinin metabolism pathway in the rat pulmonary circulation","volume":"10","author":"Pesquero","year":"1992","journal-title":"J Hypertens."},{"key":"B78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/HYPERTENSIONAHA.106.085761","article-title":"Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries","volume":"50","author":"Sivieri","year":"2007","journal-title":"Hypertension"},{"key":"B79","doi-asserted-by":"publisher","first-page":"H3550","DOI":"10.1152\/ajpheart.00784.2007","article-title":"Carboxypeptidase B and other kininases of the rat coronary and mesenteric arterial bed perfusates","volume":"293","author":"Oliveira","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1755-5922.12053","article-title":"Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat","volume":"32","author":"Dalzell","year":"2014","journal-title":"Cardiovasc Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"H1664","DOI":"10.1152\/ajpheart.1999.276.5.H1664","article-title":"Effects of aminopeptidase P inhibition on kinin-mediated vasodepressor responses","volume":"276","author":"Kitamura","year":"1999","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/00005344-199707000-00014","article-title":"Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation","volume":"30","author":"Ersahin","year":"1997","journal-title":"J Cardiovasc Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/00005344-200104000-00002","article-title":"Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed","volume":"37","author":"Dumoulin","year":"2001","journal-title":"J Cardiovasc Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/sj.bjp.0701501","article-title":"Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart","volume":"122","author":"Dendorfer","year":"1997","journal-title":"Br J Pharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02969400","article-title":"Degradation of bradykinin, a cardioprotective substance, during a single passage through isolated rat-heart","volume":"29","author":"Ahmad","year":"2006","journal-title":"Arch Pharm Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"H418","DOI":"10.1152\/ajpheart.00677.2002","article-title":"Cardiac kinin level in experimental diabetes mellitus: role of kininases","volume":"285","author":"Koch","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.bjp.0704862","article-title":"Bradykinin potentiation by ACE inhibitors: a matter of metabolism","volume":"137","author":"Tom","year":"2002","journal-title":"Br J Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0014-2999(00)00744-5","article-title":"Vascular catabolism of bradykinin in the isolated perfused rat kidney","volume":"407","author":"Bagate","year":"2000","journal-title":"Eur J Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/psc.712","article-title":"Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry","volume":"12","author":"Ramirez-Molina","year":"2006","journal-title":"J Pept Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1161\/01.CIR.99.15.1984","article-title":"Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase","volume":"99","author":"Kokkonen","year":"1999","journal-title":"Circulation"},{"key":"B91","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/ki.1987.239","article-title":"Role of renal endopeptidase 24","volume":"32","author":"Ura","year":"1987","journal-title":"in vitroin vivo. Kidney Int."},{"key":"B92","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/hy0202.103298","article-title":"Neprilysin inhibitors potentiate effects of bradykinin on B2 receptor","volume":"39","author":"Deddish","year":"2002","journal-title":"Hypertension"},{"key":"B93","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0008-6363(02)00284-5","article-title":"Kinins, the long march\u2013a personal view","volume":"54","author":"Erdos","year":"2002","journal-title":"Cardiovasc Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3109\/10641969409078026","article-title":"The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats","volume":"16","author":"Ura","year":"1994","journal-title":"Clin Exp Hypertens."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3109\/10641969509037403","article-title":"The mechanisms of the renal effects of neutral endopeptidase inhibitor in rats","volume":"17","author":"Ura","year":"1995","journal-title":"Clin Exp Hypertens."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3109\/10641969509037405","article-title":"The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in normotensive and hypertensive rats","volume":"17","author":"Nomura","year":"1995","journal-title":"Clin Exp Hypertens."},{"key":"B97","doi-asserted-by":"publisher","first-page":"F1417","DOI":"10.1152\/ajprenal.1990.258.5.F1417","article-title":"Interaction of ANP and bradykinin during endopeptidase 24","volume":"258","author":"Smits","year":"1990","journal-title":"Am J Physiol Renal Physiol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI116009","article-title":"Renal tubular responsiveness to atrial natriuretic peptide in sodium-retaining chronic caval dogs","volume":"90","author":"Legault","year":"1992","journal-title":"J Clin Invest."},{"key":"B99","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0022-3565(25)20262-2","article-title":"Thiorphan-induced natriuresis in volume-expanded rats: roles of endogenous atrial natriuretic factor and kinins","volume":"258","author":"Bralet","year":"1991","journal-title":"J Pharmacol Exp Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0014-2999(95)00706-7","article-title":"Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin","volume":"296","author":"Pham","year":"1996","journal-title":"Eur J Pharmacol."},{"key":"B101","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005344-199702000-00014","article-title":"Effect of neutral endopeptidase 24","volume":"29","author":"Yang","year":"1997","journal-title":"J Cardiovasc Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00210-002-0600-8","article-title":"Effects of neutral endopeptidase 24","volume":"366","author":"Nakano","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/01.RES.75.4.770","article-title":"Neutral endopeptidase in the heart: neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation","volume":"75","author":"Piedimonte","year":"1994","journal-title":"Circ Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/00005344-199804000-00023","article-title":"Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism","volume":"31","author":"Zhang","year":"1998","journal-title":"J Cardiovasc Pharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"B106","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1124\/jpet.103.064105","article-title":"The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24","volume":"309","author":"Sulpizio","year":"2004","journal-title":"J Pharmacol Exp Ther."},{"key":"B108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/01.HYP.19.3.281","article-title":"Inhibition by converting enzyme inhibitors of pig kidney aminopeptidase P","volume":"19","author":"Hooper","year":"1992","journal-title":"Hypertension"},{"key":"B109","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"B111","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"R1059","DOI":"10.1152\/ajpregu.2001.281.4.R1059","article-title":"Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans","volume":"281","author":"Campbell","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/01.HYP.0000054976.67487.08","article-title":"Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans","volume":"41","author":"Zeitz","year":"2003","journal-title":"Hypertension"},{"key":"B114","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00005344-199508000-00009","article-title":"Effects of losartan on angiotensin and bradykinin peptides, and angiotensin converting enzyme","volume":"26","author":"Campbell","year":"1995","journal-title":"J Cardiovasc Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1161\/HYPERTENSIONAHA.113.02902","article-title":"Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism","volume":"63","author":"Koid","year":"2014","journal-title":"Hypertension"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1161\/01.HYP.0000064942.77814.26","article-title":"AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin\/B2-receptor-dependent mechanism","volume":"41","author":"Hornig","year":"2003","journal-title":"Hypertension"},{"key":"B117","first-page":"24","article-title":"The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts","volume":"3","author":"Wiemer","year":"1993","journal-title":"Pharm Pharmacol Lett."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1172\/JCI119360","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure - Role of kinins and angiotensin II type 2 receptors","volume":"99","author":"Liu","year":"1997","journal-title":"J Clin Invest."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/S0735-1097(98)00441-0","article-title":"Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs","volume":"32","author":"Jalowy","year":"1998","journal-title":"J Am Coll Cardiol."},{"key":"B120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00005344-199905000-00016","article-title":"Bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts","volume":"33","author":"Zhu","year":"1999","journal-title":"J Cardiovasc Pharmacol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"III346-51","DOI":"10.1161\/01.CIR.102.suppl_3.III-346","article-title":"Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms","volume":"102","author":"Sato","year":"2000","journal-title":"Circulation"},{"key":"B122","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/01.HYP.35.1.155","article-title":"Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function","volume":"35","author":"Carey","year":"2000","journal-title":"Hypertension"},{"key":"B123","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1161\/01.HYP.0000090323.58122.5C","article-title":"Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice","volume":"42","author":"Abadir","year":"2003","journal-title":"Hypertension"},{"key":"B124","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1124\/jpet.107.124859","article-title":"Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia","volume":"323","author":"Messadi-Laribi","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"B125","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","article-title":"Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects","volume":"339","author":"Gainer","year":"1998","journal-title":"N Engl J Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/hyp.36.1.132","article-title":"Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men","volume":"36","author":"Squire","year":"2000","journal-title":"Hypertension"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1124\/jpet.106.117259","article-title":"Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade","volume":"320","author":"LeFebvre","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1046\/j.1440-1681.2001.03564.x","article-title":"The kallikrein-kinin system in humans","volume":"28","author":"Campbell","year":"2001","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B129","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/BF00788284","article-title":"Plasma exudation in conscious dogs with experimental heart failure","volume":"89","author":"Rubinstein","year":"1994","journal-title":"Basic Res Cardiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00257\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T21:58:00Z","timestamp":1751925480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00257\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":129,"alternative-id":["10.3389\/fmed.2018.00257"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2018.00257","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"article-number":"257"}}